IMMX PE Ratio & Valuation,Is IMMX Overvalued

IMMX Relative Valuation

IMMX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMMX is overvalued; if below, it's undervalued.

Historical Valuation

Immix Biopharma Inc (IMMX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.78. The fair price of Immix Biopharma Inc (IMMX) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：6.36

Fair

-10.02

-9.02

EV/EBITDA

Immix Biopharma Inc. (IMMX) has a current EV/EBITDA of -9.02. The 5-year average EV/EBITDA is -2.35. The thresholds are as follows: Strongly Undervalued below -6.79, Undervalued between -6.79 and -4.57, Fairly Valued between -0.13 and -4.57, Overvalued between -0.13 and 2.09, and Strongly Overvalued above 2.09. The current Forward EV/EBITDA of -9.02 falls within the Strongly Undervalued range.

-6.62

EV/EBIT

Immix Biopharma Inc. (IMMX) has a current EV/EBIT of -6.62. The 5-year average EV/EBIT is -2.16. The thresholds are as follows: Strongly Undervalued below -6.21, Undervalued between -6.21 and -4.18, Fairly Valued between -0.13 and -4.18, Overvalued between -0.13 and 1.90, and Strongly Overvalued above 1.90. The current Forward EV/EBIT of -6.62 falls within the Strongly Undervalued range.

0.00

Immix Biopharma Inc. (IMMX) has a current PS of 0.00. The 5-year average PS is 5.46. The thresholds are as follows: Strongly Undervalued below -37.38, Undervalued between -37.38 and -15.96, Fairly Valued between 26.88 and -15.96, Overvalued between 26.88 and 48.31, and Strongly Overvalued above 48.31. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Immix Biopharma Inc. (IMMX) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.09. The thresholds are as follows: Strongly Undervalued below -4.40, Undervalued between -4.40 and -2.74, Fairly Valued between 0.57 and -2.74, Overvalued between 0.57 and 2.23, and Strongly Overvalued above 2.23. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Immix Biopharma Inc. (IMMX) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Immix Biopharma Inc (IMMX) has a current Price-to-Book (P/B) ratio of 28.26. Compared to its 3-year average P/B ratio of 4.95 , the current P/B ratio is approximately 471.03% higher. Relative to its 5-year average P/B ratio of 4.09, the current P/B ratio is about 590.23% higher. Immix Biopharma Inc (IMMX) has a Forward Free Cash Flow (FCF) yield of approximately -6.51%. Compared to its 3-year average FCF yield of -23.77%, the current FCF yield is approximately -72.62% lower. Relative to its 5-year average FCF yield of -20.95% , the current FCF yield is about -68.93% lower.

24.82

P/B

Median3y

4.95

Median5y

4.09

-6.51

FCF Yield

Median3y

-23.77

Median5y

-20.95

Competitors Valuation Multiple

The average P/S ratio for IMMX's competitors is 0.00, providing a benchmark for relative valuation. Immix Biopharma Inc Corp (IMMX) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of IMMX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of IMMX in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Immix Biopharma Inc (IMMX) currently overvalued or undervalued?

What is Immix Biopharma Inc (IMMX) fair value?

IMMX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Immix Biopharma Inc (IMMX) is between to according to relative valuation methord.

How does IMMX's valuation metrics compare to the industry average?

What is the current P/B ratio for Immix Biopharma Inc (IMMX) as of Dec 16 2025?

As of Dec 16 2025, Immix Biopharma Inc (IMMX) has a P/B ratio of 28.26. This indicates that the market values IMMX at 28.26 times its book value.

What is the current FCF Yield for Immix Biopharma Inc (IMMX) as of Dec 16 2025?

As of Dec 16 2025, Immix Biopharma Inc (IMMX) has a FCF Yield of -6.51%. This means that for every dollar of Immix Biopharma Inc’s market capitalization, the company generates -6.51 cents in free cash flow.

What is the current Forward P/E ratio for Immix Biopharma Inc (IMMX) as of Dec 16 2025?

As of Dec 16 2025, Immix Biopharma Inc (IMMX) has a Forward P/E ratio of -11.40. This means the market is willing to pay $-11.40 for every dollar of Immix Biopharma Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Immix Biopharma Inc (IMMX) as of Dec 16 2025?

As of Dec 16 2025, Immix Biopharma Inc (IMMX) has a Forward P/S ratio of 0.00. This means the market is valuing IMMX at $0.00 for every dollar of expected revenue over the next 12 months.

IMMX Valuation

IMMX Valuation

IMMX Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is Immix Biopharma Inc (IMMX) currently overvalued or undervalued?

What is Immix Biopharma Inc (IMMX) fair value?

How does IMMX's valuation metrics compare to the industry average?

What is the current P/B ratio for Immix Biopharma Inc (IMMX) as of Dec 16 2025?

What is the current FCF Yield for Immix Biopharma Inc (IMMX) as of Dec 16 2025?

What is the current Forward P/E ratio for Immix Biopharma Inc (IMMX) as of Dec 16 2025?

What is the current Forward P/S ratio for Immix Biopharma Inc (IMMX) as of Dec 16 2025?